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to develop a safe and effective protocol to
create induced pluripotent stem cells.
Time will tell if this protocol will have clin-
ical utility in this important area of biomed-
ical research.REFERENCES
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Humans are uniquely susceptible to typhoid fever caused by infection with Salmonella enterica
serovar Typhi. Mathur et al. now report that mice lacking Toll-like receptor 11, which is absent in
humans, can be lethally infected with S. Typhi, a breakthrough that promises to speed the develop-
ment of better vaccines.Typhoid fever is a global health pro-
blem estimated to cause more than
20,000,000 infections each year, resulting
in more than 200,000 deaths (Crump
et al., 2004). Although much has been
learned about the pathogenesis of Salmo-
nella infections in recent decades,
studying S. Typhi has remained a chal-
lenge due to its exquisite specificity for
the human host. In this issue, Mathur
et al. (2012) report the breakthrough
discovery that mice lacking the innate
immunity receptor TLR11 can be lethally
infected with S. Typhi via an oral route of
infection. This promises to expand our
understanding of typhoid pathogenesis
and speed the development of better
typhoid vaccines.
The clinical manifestations of typhoid
are distinct from those of otherSalmonella
serovars such as S. Typhimurium, which
typically cause self-limiting inflammatory
diarrhea. In contrast, S. Typhi causes adebilitating systemic illness following a
prolonged incubation period with absent
or mild gastrointestinal symptoms (Parry
et al., 2002). Immunity to nontyphoidal
and typhoidal infections also appears to
differ in fundamental respects, as individ-
uals with chronic granulomatous disease,
HIV infection, or other impairment of
the interferon-g/interleukin-12 (IFNg/IL-
12) signaling axis exhibit enhanced
susceptibility to nontyphoidal salmonel-
losis, but not to typhoid fever (Gordon,
2008). The S. Typhi genome shows the
presence of a number of putative and
confirmed virulence determinants, such
as the Vi capsular polysaccharide and
typhoid toxin, that are not found in
S. Typhimurium. Conversely, there is also
evidence of considerable genomic decay
inS. Typhi, with a large number of pseudo-
genes that have presumably undergone
mutation following the evolutionary adap-
tation of S. Typhi to a narrow host range(Parkhill et al., 2001). It is generally
assumed that genomic decay resulted in
the loss of factors conferring resistance
to host defense mechanisms that are
absent in humans but present in other
mammalian species. However, the iden-
tity of such host defense mechanisms
has remained an enigma.
TLR11 is a Toll-like innate immune
receptor that is expressed by mice, but
not by humans. A previous study reported
that TLR11 recognizes the parasitic
protein profilin and regulates immune
responses to Toxoplasma gondii (Yaro-
vinsky et al., 2005). The new study shows
that TLR11, like another Toll-like receptor
called TLR5, can also recognize bacterial
flagellar protein. TLR11 is highly ex-
pressed at mucosal surfaces, such as
the bladder and intestinal epithelium, but
is also expressed in viscera such as the
liver and spleen and by macrophages,
particularly in the absence of TLR5., October 26, 2012 ª2012 Elsevier Inc. 473
Figure 1. TLR11-Mediated Innate Immunity to Salmonella Typhi in the Mouse Intestine
TLR11 is expressed by small intestinal epithelial cells and by mononuclear phagocytes in the lamina
propria. Mathur et al. (2012) report that TLR11 recognition of the Salmonella Typhi flagellin protein
enhances epithelial resistance to bacterial invasion and promotes cytokine production by mononuclear
cells to enhance systemic resistance to bacterial dissemination. This may help to account for the speci-
ficity of S. Typhi for humans, who lack TLR11 expression.TLR11 appears to control the expression
of proinflammatory cytokines such as
IL-6 and IL-12 (Figure 1). Mathur et al.
(2012) show that TLR11-deficient mice
are susceptible to S. Typhi infection by
both oral and intraperitoneal routes of
infection, suggesting that the presence
of TLR11 may help to explain the intrinsic
resistance of mice to S. Typhi infection.
TLR11-deficient mice are also more sus-
ceptible to nontyphoidal S. Typhimurium.
This contrasts with TLR5-deficient
mice, which are more resistant to Salmo-
nella infection. S. Typhi appears to be
missing virulence factors that allow
S. Typhimurium and other nontyphoidal
Salmonella serovars to overcome the
TLR11 barrier, although previous
attempts to render S. Typhi virulent for
mice by introducing S. Typhimurium DNA
have not been successful.
A few caveats should be mentioned. If
TLR11 activation by S. Typhi flagellin is
indeed responsible for the resistance of
mice to typhoid, then the abrogation of
either TLR11 or flagellin expression would474 Cell 151, October 26, 2012 ª2012 Elsevibe predicted to render S. Typhi virulent in
themousemodel. TLR11 deficiency in the
host does in fact have the predicted
effect, but a bacterial flagellar mutant
does not. This suggests the possibility
that other bacterial ligands in addition to
flagellin might be able to stimulate
TLR11. An alternative possibility is that
flagella are essential for S. Typhi virulence
due to a TLR11-independent mechanism.
This would not have been anticipated,
given the dispensibility of flagella for
S. Typhimurium virulence in the mouse
model (Lockman and Curtiss, 1990), but
must be seriously considered in view of
observations by Mathur et al. (2012) and
others that aflagellate S. Typhi mutants
exhibit reduced growth in human macro-
phages (Sabbagh et al., 2012).
Another open question is whether the
TLR11-deficient mouse faithfully recapit-
ulates the immunological and patholog-
ical features of human typhoid. Following
high-dose oral S. Typhi administration,
TLR11-deficient mice develop intense
destruction of the intestinal mucosa ander Inc.bloody diarrhea. Although gastrointestinal
bleeding and even intestinal perforation
have been described as late complica-
tions (Parry et al., 2002), severe intestinal
destruction is not typically characteristic
of human typhoid. The production of
IL-12 is also striking and somewhat unex-
pected, given the lack of apparent
involvement of IFNg-IL-12 signaling in
human typhoid. Protection against an
S. Typhi challenge is conferred by adop-
tive transfer of serum, implying the in-
volvement of specific antibody. However,
although a robust antibody response to
the Vi capsular antigen is protective
against typhoid, considerable evidence
argues for the importance of cellular
responses in typhoid immunity (Sztein,
2007). Further pathological and immuno-
logical characterization of experimental
S. Typhi infection in TLR11-deficient
mice will be of considerable interest.
This will be especially important when
evaluating the suitability of the TLR11-
deficient mouse as a model for the
evaluation of novel typhoid vaccine
candidates.
Humanized mice engrafted with human
hematopoietic cells have recently been
shown to be susceptible to S. Typhi infec-
tion and appear to exhibit some of the
pathological and immunological charac-
teristics of human typhoid (Libby et al.,
2010). However, TLR11-deficient mice
have the potential to provide a less costly
alternative that does not require the trans-
plantation of human tissue and exhibits
less animal-to-animal variability. The
TLR11-deficient mouse may also be
useful for the study of other human enteric
pathogens that are unable to cause infec-
tions inmice. The development ofmultiple
small animal models for typhoid is an
exciting development that is expected to
yield important new insights into the path-
ogenesis and immunity of this enigmatic
and neglected disease.
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